NCT05055193

Outcome of Extremely Preterm Infants Who Received Systemic Postnatal Corticosteroid for Bronchopulmonary Dysplasia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 400 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Bronchopulmonary dysplasia is a complication of prematurity. Postnatal corticosteroid is used to treat the inflammatory part of this pathology, in particular to wean premature infants from the ventilator at the end of the first month of life. However, this therapy remains controversial because it may induce suboptimal neurocognitive development. Parents of infants who receive postnatal corticosteroid should be provided with information about the risks. The objective of our work was to evaluate the respiratory, neurodevelopmental and growth outcomes at 24 months corrected age of extremely preterm infants who received postnatal corticosteroid.

Conditions

• Bronchopulmonary Dysplasia

Interventions

Type	Name	Description
DRUG	Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome	Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.

Timeline

• Start date: 2013-01-01
• Primary completion: 2013-01-01
• Completion: 2018-12-31
• First posted: 2021-09-24
• Last updated: 2021-09-24

Locations

1 site across 1 country: France